Nanoviricides, Inc. NNVC
Nanoviricides, Inc. (NYSE: NNVC) is an infectious disease drug developer. Its lead program, NV-387, is in Phase 1 for viral infections: Mpox, Ebola, COVID-19, viral acute respiratory infections (RSV, influenza, coronaviruses, hMPV). Its next catalyst on record is NV-387 (Mpox): Initiation of Phase II trial (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NV-387 (Mpox) — Initiation of Phase II trial (date not stated). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NV-387 (Mpox, oral gummies) | Mpox | small molecule | Phase 1 |
| NV-387 (Ebola, oral gummies) | Ebola (Bundibugyo outbreak, DRC) | small molecule | Phase 1 |
| NV-387 (COVID, NV-CoV-2 oral syrup/gummies) | COVID-19 | small molecule | Phase 1 |
| NV-387 (Viral ARI/SARI) | influenza, RSV, coronaviruses, hMPV | small molecule | Pre-clinical |
| RSV, FluCide, HerpeCide, HIVCide programs | RSV, influenza, herpes, HIV | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.